title: Intrathecal chemotherapy with MX2 for treating glioma dissemination in vivo.
abstract: We examined whether the intrathecal MX2 chemotherapy for treating dissemination of malignant glioma would be a feasible therapy. In the toxicity study, physiological and histological neurotoxicity was not observed in the rats treated with less than 100 microg/kg of MX2 administered intracisternally. But physiological side effects were observed in the treatment group of more than 200 microg/kg and histological brain toxicity was in the treatment group of more than 1000 microg/kg. Dissemination models were induced in rats by intracisternal inoculation of C6 glioma cells. The median survival times of the rats treated with 100 microg/kg of intrathecal MX2 on day 1, 3, or 7 after tumor inoculation were prolonged by 52.4% (p = 0.0006), 31.5% (p = 0.0007), and 7.1% (p = 0.0180), respectively, compared to that of untreated control animals. Intrathecal MX2 treatment also cured 33.6% of rats in the treatment group. These findings suggested that there was a possibility that intrathecal MX2 would be a safe and effective method for treating dissemination of malignant glioma.
authors.affiliation: Department of Neurological Surgery, Okayama University Medical School, Japan. smizu@ehm.enjoy.ne.jp
authors.forename: S
authors.initials: S
authors.lastname: Mizumatsu
authors.forename: K
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Y
authors.initials: Y
authors.lastname: Ono
authors.forename: T
authors.initials: T
authors.lastname: Tamiya
authors.forename: T
authors.initials: T
authors.lastname: Furuta
authors.forename: T
authors.initials: T
authors.lastname: Ohmoto
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000473:pathology; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D002360:Carubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005240:Feasibility Studies; D005910:Glioma / Q000188:drug therapy* / Q000556:secondary*; D007276:Injections, Intraventricular; D007278:Injections, Spinal; D008297:Male; D009422:Nervous System Diseases / Q000139:chemically induced; D051381:Rats; D017208:Rats, Wistar; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; C053537:morpholinoanthracycline MX2; D002360:Carubicin